Varian Medical Systems Inc
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
Danaher Corporation’s Excess Returns Fail to Impress
Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.
Varian’s Halcyon Treatment System Sees Emerging Market Demand
Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]
What to Expect from Varian’s Bottom Line in Q4 2018
Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.
Here’s What Varian Medical Systems’ Valuation Trend Indicates
Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”
Understanding Varian Medical Systems’ Business Segments
Revenues from the Oncology Systems segment increased from $564.4 million in fiscal Q3 2017 to $667.2 million in fiscal Q3 2018.
Why ViewRay Stock Fell 9.4% on August 3
On August 3, ViewRay (VRAY) reported revenues of $16.4 million for Q2 2018, which is a YoY rise of 2,248.6%.
How Baxter International Fared in the Second Quarter
Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.
What to Expect from Varian Medical Systems’ Q3 2018 Earnings
Varian Medical Systems (VAR) is expected to report its Q3 2018 earnings on July 25. Analysts expect its revenues to increase 0.30%.
Insights on Varian’s Acquisition Deal with Sirtex Medical
On January 30, Varian Medical Systems (VAR) entered into an agreement to acquire Australian company Sirtex Medical for $1.2 billion, at 28 Australian dollars per share.
Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.
Varian Medical Systems and International Market Penetration
In 1Q18, Varian Medical Systems (VAR) reported revenues of $356.7 million from the Americas region, which was a YoY (year-over-year) growth of 20%.
Rationale behind Varian Medical’s Acquisition of Sirtex Medical
On January 30, 2018, Varian Medical Systems (VAR) announced that it had entered into an agreement to acquire Sirtex Medical Limited for $1.3 billion.
ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates
Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.
Will Varian Medical Systems’ Sales Decline Again in 1Q18?
According to Wall Street analysts’ estimates, Varian Medical Systems (VAR) will report revenues of $636.8 million in 1Q18, a YoY decline of 16.6%.
A Look at Varian Medical Systems’ Long-Term Objectives
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
Healthcare Was September Loser for US Domestic Moats
The healthcare sector has been the most challenged sector since the presidential elections in November 2016.
Intuitive Surgical’s Recent Stock Split: The Market Reaction
On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.
How Varian Is Harnessing Proton Therapy Market Opportunities
Proton therapy market opportunities The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report, the global proton therapy market is expected to double by the year 2022. Though the United States has the biggest proton […]
Why Varian Medical Systems’ Profitability Is Improving
Varian Medical Systems’ profitability In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis points. In 3Q17, the company’s Oncology Systems business witnessed a gross margin improvement of 200 basis points to reach 48.1% of the segment’s total […]
Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
Varian Medical Systems: Analyzing Its Stock Performance
Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.
Could It Be Time to Buy US Domestic Moats?
VanEck U.S. Domestic Moats: Buy Buy Baby (Contd..) It’s been a wild ride for pharmaceutical and biotech companies since last year’s U.S. presidential election, but Morningstar’s economic moat and valuation research within both industries benefited the U.S. Moat Index as several of the top drivers of performance came from within those industries. Materials firm Compass […]
How Did Danaher’s Operating Segments Fare in 4Q16?
Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Why Danaher Stock Rose after Its 4Q16 Results
Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.
What Factors Could Drive Danaher Stock in 2017?
Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?
Analyzing Morningstar’s Economic Moat Rating
Morningstar first began rating companies in 2002 according to the strength and longevity of their competitive advantages.
Moat Investing: Staying Ahead of the Competition
Moat companies offer long-term outperformance compared to benchmarks.
Varian Medical Systems Attempts to Improve Its Performance Growth
Varian Medical Systems (VAR) raised its guidance for fiscal 2016 in the view of higher-than-expected 3Q16 results reported on July 27.
How Are Danaher’s Returns Compared to Its Industry Peers’?
Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.
What’s Varian’s Product Strategy for Its Oncology Business?
Varian Medical Systems’ (VAR) radiation oncology business has a strong foothold around the world.
How Is Varian Positioned in the Particle Therapy Business?
Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.
Growth Strategies Driving Varian Medical Systems’ Revenue
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Varian Medical Systems’ Growth Potential in Radiation Oncology
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
Where Does Varian Medical Systems Get Most of Its Revenue?
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.
XLV’s Mid-October Performance amid Falling Biotech Stocks
On October 20, biotech stocks again witnessed a sell-off, causing the major biotech ETFs to finish the day in the red. XLV similarly fell by 1.55%.
Top Ten Mid-Cap Stocks Outperformed SPY on October 12
Varian Medical Systems (VAR) fell by 1.5% and closed at $76.82 on October 12. The stock fell on profit booking, breaking its three-day upward trend.